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Summary
Background Current rheumatoid arthritis therapies target immune inflammation and are subject to ceiling effects. 
Seliciclib is an orally available cyclin-dependent kinase inhibitor that suppresses proliferation of synovial fibroblasts—
cells not yet targeted in rheumatoid arthritis. Part 1 of this phase 1b/2a trial aimed to establish the maximum tolerated 
dose of seliciclib in patients with active rheumatoid arthritis despite ongoing treatment with TNF inhibitors, and to 
evaluate safety and pharmacokinetics.
Methods Phase 1b of the TRAFIC study was a non-randomised, open-label, dose-finding trial done in rheumatology 
departments in five UK National Health Service hospitals. Eligible patients (aged ≥18 years) fulfilled the 1987 American 
College of Rheumatology (ACR) or the 2010 ACR–European League Against Rheumatism classification criteria for 
rheumatoid arthritis and had moderate to severe disease activity (a Disease Activity Score for 28 joints [DAS28] of ≥3·2) 
despite stable treatment with anti-TNF therapy for at least 3 months before enrolment. Participants were recruited 
sequentially to a maximum of seven cohorts of three participants each, designated to receive seliciclib 200 mg, 400 mg, 
600 mg, 800 mg, or 1000 mg administered in 200 mg oral capsules. Sequential cohorts received doses determined by a 
restricted, one-stage Bayesian continual reassessment model, which determined the maximum tolerated dose (the 
primary outcome) based on a target dose-limiting toxicity rate of 35%. Seliciclib maximum concentration (Cmax) and area 
under the plasma concentration time curve 0–6 h (AUC0–6) were measured. This study is registered with ISRCTN, 
ISRCTN36667085.
Findings Between Oct 8, 2015, and Aug 15, 2017, 37 patients were screened and 15 were enrolled to five cohorts and 
received seliciclib, after which the trial steering committee and the data monitoring committee determined that the 
maximum tolerated dose could be defined. In addition to a TNF inhibitor, ten (67%) enrolled patients were taking 
conventional synthetic disease modifying antirheumatic drugs. The maximum tolerated dose of seliciclib was 400 mg, 
with an estimated dose-limiting toxicity probability of 0·35 (90% posterior probability interval 0·18–0·52). Two serious 
adverse events occurred (one acute kidney injury in a patient receiving the 600 mg dose and one drug-induced liver 
injury in a patient receiving the 400 mg dose), both considered to be related to seliciclib and consistent with its known 
safety profile. 65 non-serious adverse events occurred during the trial, 50 of which were considered to be treatment 
related. Most treatment-related adverse events were mild; 20 of the treatment-related non-serious adverse events 
contributed to dose-limiting toxicities. There were no deaths. Average Cmax and AUC0–6 were two-times higher in 
participants developing dose-limiting toxicities.
Interpretation The maximum tolerated dose of seliciclib has been defined for rheumatoid arthritis refractory to TNF 
blockade. No unexpected safety concerns were identified to preclude ongoing clinical evaluation in a formal efficacy trial.
Funding UK Medical Research Council, Cyclacel, Research into Inflammatory Arthritis Centre (Versus Arthritis), and 
the National Institute of Health Research Newcastle and Birmingham Biomedical Research Centres and Clinical 
Research Facilities.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Chronic, painful inflammation, synovial hypertrophy, 
and associated structural and functional deterioration of 
peripheral joints are hallmarks of rheumatoid arthritis. 
They account for the considerable burden of disability, 
work instability, and mortality posed by a disease with a 
global prevalence approaching 20 million.1 Recent years 
have seen a revolution in the management of rheumatoid 
arthritis, reflecting both a recognition that timely and 
sustained suppression of inflammation improves 
outcomes and a growing array of available therapies that 
target immune cells or cytokine signalling. Such drugs 
show a similar pattern of efficacy, including ceiling effects, 
irrespective of their target. Non-response is observed in a 
third of recipients, and true remission—the absence of 
clinical signs and symp toms of active rheumatoid 
arthritis—is uncommon.2 Furthermore, some patients 
with refractory disease have clinically synovitic joint 
swelling but only grey-scale changes on musculoskeletal 
ultrasonography without Doppler activity, implying a 
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non-inflammatory patho genesis to their synovitis. 
Emerging insights into the molecular events underpinning 
rheumatoid arthritis increasingly high light the stromal 
compartment—specifically, synovial fibroblasts—as 
crucial drivers of chronicity that have yet to be directly or 
explicitly targeted in clinical practice. Early in the natural 
history of the disease, synovial fibroblasts adopt hyper-
plastic, prolifera tive phenotypes that perpetuate chronic 
inflam mation or mediate the destruction of cartilage and 
bone.3 Conceivably, synovial fibroblast biology could 
under pin grey-scale synovitis, as well as the ceiling effects 
of current targeted therapies. Approaches that modulate 
synovial fibroblast pathobiology might therefore be 
required to synergise with current immunomodulatory 
strategies to reliably induce sustained remission in 
patients with rheumatoid arthritis.
Seliciclib is an orally available cyclin-dependent kinase 
(CDK) inhibitor under development for oncology indica-
tions. Seliciclib suppresses synovial fibroblast pro lifer-
ation, not only by inhibiting CDK2, but also by inducing 
expression of the endogenous CDK inhibitor p21, which is 
otherwise downregulated in synovial fibroblasts in patients 
with rheumatoid arthritis.4,5 In addition, inhibition of 
CDK7 and CDK9 by seliciclib reduces trans crip tion of the 
B-cell lymphoma-2 (BCL-2) family member MCL1, leading 
to impaired viability of neutrophils, synovial macrophages, 
and synovial fibroblasts.6 Seliciclib and related CDK 
inhibitors have shown efficacy and potency in preclinical 
arthritis models.7 Unlike other CDK inhibitors, seliciclib is 
not myelo suppressive;8 its reported toxicity profile is other-
wise similar to that of existing conventional synthetic 
disease-modifying antirheumatic drugs (DMARDs).
These observations, together with evidence from genetic 
studies that suggest CDK inhibition as a plausible thera-
peutic strategy in rheumatoid arthritis,9 support our hypo-
thesis that seliciclib could be a viable repurposing option 
for the management of patients with rheumatoid arthritis 
with disease that is refractory to drugs that target immune 
inflammation. Our aim was to determine the maximum 
tolerated dose of seliciclib in patients with active rheu-
matoid arthritis despite treatment with TNF inhibitors, 
either as monotherapy or with background conven tional 
synthetic DMARDs. We also aimed to assess safety in this 
patient group, to assess the relationship between 
pharmacokinetic and pharmacodynamic para meters and 
seliciclib toxicity, and to examine any effect on circulating 
autoantibody status or patient-reported fatigue. Partici-
pants’ disease activity over time was also evaluated.
Methods 
Study design and participants 
The TRAFIC study is a two part, multicentre, phase 1b/2a 
trial investigating the safety, tolerability, and potential 
activity of seliciclib as an addition to biologic therapy in 
participants with active rheumatoid arthritis; the protocol 
has been published elsewhere.10 Here, we report results 
of the phase 1b component: a non-randomised, 
open-label, dose-finding trial done in rheumatology 
clinics at five UK National Health Service (NHS) 
hospitals. Adult patients (aged ≥18 years) were eligible 
for inclusion if they fulfilled the 1987 American College 
of Rheumatology (ACR) or the 2010 ACR–European 
League Against Rheumatism classification criteria for 
rheumatoid arthritis11 and had moderate to severe disease 
Research in context
Evidence before this study
Despite accumulating experimental data supporting a crucial 
role for synovial fibroblasts as drivers of rheumatoid arthritis, 
efforts to target them in the clinic remain in their infancy. 
We searched PubMed, Embase, and ClinicalTrials.gov for studies 
with abstracts in English published before Nov 20, 2020, for 
clinical trials targeting synovial fibroblasts in rheumatoid 
arthritis and adaptive trial designs applied in the condition 
(see appendix p 1 for search terms and strategy). Three clinical 
trials of drugs targeting the adhesive properties or crosstalk of 
synovial fibroblasts via cadherin-11, integrin-α9, and fractalkine 
were identified; the studies on cadherin-11 and integrin-α9 
have reported negative outcomes and efficacy data for 
fractalkine are awaited. No studies have directly targeted the 
proliferative capacity of synovial fibroblasts for the treatment 
of rheumatoid arthritis, via cyclin-dependent kinase (CDK) 
inhibition or otherwise. Adaptive designs for early phase trials 
of this kind, although established in oncology, are rare in 
rheumatic and musculoskeletal diseases; of two such trials in 
rheumatoid arthritis identified by our search, neither used the 
Bayesian continual reassessment method.
Added value of this study
We found the maximum tolerated dose of seliciclib, an orally 
available CDK inhibitor, in a phase 1b trial among patients 
with rheumatoid arthritis refractory to TNF blockade, further 
evaluating the safety and tolerability of the intervention. 
We used the Bayesian continual reassessment method, 
showing it to be efficient for the purposes of dose-finding in 
this setting. Maximum tolerated dose was derived with a high 
level of confidence after enrolment of just 15 patients into 
our trial, considerably fewer than would have been required in 
a more conventional 3 + 3 design, enabling expeditious 
clinical development.
Implications of all the available evidence
This study paves the way for formal efficacy evaluation of 
seliciclib to target synovial fibroblast proliferation as a novel 
strategy in refractory rheumatoid arthritis, and establishes 
the continual reassessment method as an important adaptive 
design to consider for future early phase trials in rheumatic 
and musculoskeletal diseases.
See Online for appendix
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activity (defined as a Disease Activity Score for 28 joints 
[DAS28] of ≥3·2)12 despite stable treatment with anti-TNF 
therapy for at least 3 months before enrolment. Any 
licensed anti-TNF drug was per missible, either as 
monotherapy or in combination with methotrexate, 
sulfasalazine, or hydroxy chloro quine (stable doses for 
≥4 weeks before the baseline visit). Patients receiving 
systemic corticosteroid therapy within 4 weeks of the 
baseline visit, except a stable dose of up to 7·5 mg 
prednisolone, were ineligible. Full eligibility criteria are 
shown in the appendix (p 2) and in the protocol.10 All 
participants provided written, informed consent before 
enrolment into the trial, which received ethical approval 
from the North East Tyne & Wear South Research Ethics 
Committee (reference number 14/NE/1075). Patient 
safety was monitored by an indepen dent data monitoring 
committee. This trial was registered on Sept 26, 2014, 
with ISRTN, ISRCTN36667085, and EudraCT, 2014-
001339-35.
Procedures 
Eligible patients joined sequentially recruited cohorts of 
three participants each. Seliciclib was bulk supplied as 
200 mg oral capsules by Cyclacel (Dundee, UK); packaging 
and labelling done by Penn Pharmaceuticals (Tredegar, 
UK). Participants could receive 200 mg, 400 mg, 600 mg, 
800 mg, or 1000 mg, taken daily for 4 consecutive days 
every week over a 4-week treatment period. Dose range 
and schedule were predetermined on the basis of healthy 
control and oncology studies in which more than 
450 participants had previously received seliciclib.10 In 
these studies, dose-limiting toxicities were reversible at 
doses of less than 1600 mg seliciclib daily. Most adverse 
events were mild to moderate in severity, dose-related, 
and generally occurred during the first 3 weeks of therapy. 
Taking into account published8,13 and unpublished data 
from the oncology field, the previous estimate of 
maximum tolerated dose was 600 mg of seliciclib; to 
exercise caution, patients enrolled into the first cohort 
were administered 400 mg, in addition to a background 
biologic drug as mono therapy or in combination with 
conventional synthetic DMARD therapy. Seliciclib was 
dispensed on a weekly basis, with unused capsules 
retrieved and counted to enable an estimation of 
compliance, which was cross-checked with patient 
diaries.
The schedule of study visits has been described 
elsewhere.10 Briefly, regular clinical assessments during 
the 4-week dosing period included measurement of 
routine laboratory parameters and an assessment of 
disease activity (herein we report DAS28–C-reactive 
protein [CRP]).12 Rheumatoid factor and anticitrullinated 
peptide autoanti bodies (ACPA) were measured in local 
NHS laboratories at baseline and at completion of 
treatment. Patient reported outcomes, collected after 0, 2, 
and 4 weeks of treatment with seliciclib, were scored on 
the 13-item Functional Assessment of Chronic Illness 
Therapy Fatigue Scale version 4 (FACIT Fatigue)14 and the 
health assessment questionnaire disability index 
(HAQ-DI).15 Seliciclib adherence was assessed by 
reconciliation of the number of tablets dispensed and 
returned. Adverse events attributed as definitely, probably, 
or possibly related to seliciclib, as well as those considered 
unrelated, were categorised as mild, moderate, or severe 
on the basis of symptoms or labora tory parameters and 
according to previously described criteria.10 Comprehensive 
safety monitoring, including the documentation of serious 
adverse events and seliciclib-related serious adverse events, 
was done according to International Conference on 
Harmon i sation Good Clinical Practice principles, and the 
expectedness of incident seliciclib-related adverse events 
was determined with reference to seliciclib’s investigator 
brochure.
The terminal half-life of seliciclib is 3–4 h, as the primary 
route of metabolism is via cytochromes 3A4 and 2B6.13,16 
To determine participant-level pharmacokinetics, blood 
samples were drawn at 0, 2, 4, and 6 h after administration 
of seliciclib on day 1 of week 1 and week 4; drug concen-
trations were measured using a validated liquid 
chromatography-tandem mass spectro metry method. 
Following calculation of the maximum concen tration 
(Cmax) and area under the plasma concen tration-time curve 
0–6 h (AUC0–6) of seliciclib, the relationship of these 
parameters with safety and tolerability in the overall trial 
population was assessed. AUC0–6 was calculated using a 
non-compartmental trapezoidal estimate.17 Based on data 
from the oncology setting, deter min ation of a maximum 
tolerated dose of 200 mg in this phase 1b trial using a 
continual reassess ment method would mandate demon-
stration of a pharmacodynamic effect at that dose to justify 
ongoing clinical development (Frame S, unpublished). 
Therefore, at the same time that blood was drawn for 
pharmacokinetics, blood was also drawn into TEMPUS 
tubes (ThermoFisher Scientific, Waltham, MA, USA) for 
RNA stabilisation to enable whole blood measurement of 
the MCL1 gene if required, with decreased expression 
expected early following target engagement by seliciclib via 
selective CDK7-mediated or CDK9-mediated inhibition.
Outcomes 
The primary objective of the phase 1b component of the 
study was identification of the maximum tolerated dose 
of seliciclib in patients with active rheumatoid arthritis 
despite treatment with anti-TNF drugs as either mono-
therapy or with background conventional synthetic 
DMARDs. The secondary objectives were to assess the 
toler ability and safety of seliciclib; to assess the relation-
ship of pharmacokinetic and pharmacodynamic bio-
markers with toxicity; to assess any effect of seliciclib on 
fatigue associated with rheumatoid arthritis; and to 
assess any effect of seliciclib on rheumatoid arthritis-
associated autoantibody status. DAS28–CRP data were 
used in a post-hoc exploratory analysis of disease activity 
over time.
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Statistical analysis 
We used a restricted, one-stage Bayesian continual re-
assess ment method18 to determine the maximum tolerated 
dose for seliciclib (200 mg, 400 mg, 600 mg, 800 mg, or 
1000 mg) over the 4-week treatment window based on a 
target dose-limiting toxicity rate of 35%. This a priori rate 
was chosen because it was similar to that seen for 
established conventional synthetic DMARDs, including 
methotrexate.19 The continual reassessment method is a 
model-based design that has been shown to be more 
accurate and potentially more efficient in identifying the 
maximum tolerated dose than traditional rule-based 
approaches such as the 3 + 3 design.20 A dose-limiting 
toxicity was defined as an adverse event or adverse reaction 
that occurred during the treatment period resulting in a 
participant’s request to withdraw or laboratory parameter 
derangement beyond predefined cutoffs, and leading to 
cessation of seliciclib.10 In the event of several adverse 
events or adverse reactions contributing to the decision to 
discontinue seliciclib, only a single dose-limiting toxicity 
was recorded for purposes of the continual reassessment 
method. Using a one-parameter logistic continual 
reassessment model, initial estimates of the probability of 
dose-limiting toxicity at each dose (the skeleton) were 
chosen via Monte Carlo simulation, evaluating objective 
performance measures under clinically relevant scenarios 
to yield a probability of 0·13 at 200 mg, 0·23 at 400 mg, 
0·35 at 600 mg, 0·47 at 800 mg, and 0·58 at 1000 mg. The 
prior standard deviation of the single model parameter 
was 0·27. Subject to approval by the sponsor and the data 
monitoring committee, each subsequent cohort’s dose was 
determined algorithmically according to the continual 
reassessment method using cumulative toxicity data, until 
the maximum tolerated dose was established. Planned 
enrolment was for a maximum of 21 patients, as seven 
cohorts of three patients each. Early termination of 
recruitment was possible at the discretion of the data 
monitoring committee and independent trial steering 
committee according to prespecified stopping rules: (1) if 
sufficient patients had been allocated to justify the current 
maximum tolerated dose estimate, and the same dose 
would be recommended for a subsequent cohort were the 
trial to continue; or (2) if the lowest dose (200 mg) was 
considered too toxic—ie, there was a high probability (>0·7) 
that the posterior probability of dose-limiting toxicity at the 
lowest dose was greater than the target dose-limiting 
toxicity rate. A full description and justification of the trial’s 
statistical design has been submitted for publication and is 
available from the authors on reasonable request.
Role of the funding source 
Cyclacel were involved in discussions regarding study 
design, contributed the study drug, funded measure ment 
of pharmacokinetics and pharmacodynamics, reviewed 
and approved the report, and had a role in data collection, 
data interpretation, and writing of the report. The funder 
had no role in data analysis. 
Results 
Between Oct 8, 2015, and Aug 15, 2017, 37 patients were 
screened and 15 were enrolled and received seliciclib 
(figure 1). 22 patients were defined as ineligible at 
Figure 1: Trial profile
All enrolled participants contributed evaluable data, no participants were lost to follow-up. *Comorbidities were determined to be unacceptable for trial entry at the discretion of the investigator in line 
with the trial protocol. †Seliciclib was taken daily for 4 consecutive days every week over a 4 week treatment period. ‡One patient had a serious adverse event: fever and acute kidney injury. 
§One patient had a serious adverse event: liver injury. 
3 enrolled in cohort 1 
(400 mg seliciclib†)
 
3 evaluable for primary 
outcome
1 dose-limiting toxicity
3 enrolled in cohort 2 
(600 mg seliciclib†)
 
3 evaluable for primary 
outcome
2 dose-limiting toxicities‡
3 enrolled in cohort 3 
(400 mg seliciclib†)
 
3 evaluable for primary 
outcome
1 dose-limiting toxicity§
3 enrolled in cohort 4 
(400 mg seliciclib†)
 
3 evaluable for primary 
outcome
1 dose-limiting toxicity
3 enrolled in cohort 5 
(400 mg seliciclib†)
 








 7 incompatible concomitant medication
 2 unacceptable comorbidities*
 4 incompatible blood test abnormalities
 8 declined participation
 1 other ineligibility, reason not recorded
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screening or, in one case, at baseline, before treatment. 
Although enrolment of up to seven cohorts of three 
participants each (21 patients in total) was specified in the 
design, the primary analysis for the trial was event-driven, 
permitting early termination of enrolment under the 
prespecified stopping rules as described.10 After treatment 
of five cohorts, the trial steering committee, in consultation 
with the data monitoring committee, determined that a 
sufficient number of patients had been treated to define 
the maxi mum tolerated dose with confidence. Enrolment 
to the phase 1b component of the trial was therefore 
concluded after 15 participants, emphasising the potential 
efficiency of such a Bayesian design. Participant baseline 
chara cteristics are shown in table 1. Documented seliciclib 
tablet reconciliation suggested 100% compliance among 
all trial participants with prescribed dosing during the 
course of the study.
The seliciclib starting dose for cohort one was 400 mg. 
Application of the continual reassessment algorithm 
prompted a single dose increment to 600 mg for 
cohort two, but reversion to 400 mg for subsequent 
cohorts (figure 1, 2A). Before enrolment of cohort six, 
four cohorts had received 400 mg seliciclib, with dose-
limiting toxicity observed in one (33%) of three patients 
in each cohort, including in three consecutive cohorts. At 
this stage, the probability that the maximum tolerated 
dose would change after completion of cohort six was 
estimated to be 0·04 and, in consultation with the data 
monitoring committee, it was therefore considered 
sufficiently well established and recruitment was stopped 
after completion of cohort five. Hence, the maximum 
tolerated dose, the dose closest to that at which 35% of 
patients have dose-limiting toxicity, was 400 mg. The 
Bayesian posterior probability of dose-limiting toxicity at 
400 mg seliciclib is 0·35 (90% posterior probability 
interval 0·18–0·52; figure 2B). Previous and Bayesian 
posterior probabilities of dose-limiting toxicity after each 
cohort’s completion are shown in the appendix (p 7).
Six (40%) of 15 patients had dose-limiting toxicity 
during the course of the trial (figure 1, 2A), all of which 
occurred within the first two treatment cycles (table 2). 
Symptoms of nausea and vomiting contributed to all but 
one of the dose-limiting toxicities (five [83%] of six, 
including both of those occurring at the 600 mg dose). 
Two serious adverse events occurred during the trial, both 
were considered to be related to seliciclib and contributed 
to two separate dose-limiting toxicities (figure 1; table 2). 
One participant (cohort two) described overnight 
symptoms of fever and gastrointestinal upset (nausea and 
vomiting) after a single dose of 600 mg seliciclib. Despite 
symptomatic improve ment on hospital assessment the 
following day, this was found to be associated with acute 
kidney injury (peak serum creatinine concentration 
203 µmol/L), and seliciclib was discontinued in this 
partici pant; renal function normalised by day 8. Another 
participant (cohort three) had a more insidious onset of 
gastro intestinal symptoms (constipation, nausea, and 
vomiting), which became associated with drug-induced 
liver injury including clinical jaundice after eight doses of 
400 mg seliciclib (peak alanine aminotransferase concen-
tration 667 U/L; peak bilirubin concentration 53 µmol/L); 
seliciclib was discontinued, with complete normalisation 
of liver function tests and symptom resolu tion confirmed 
after 7 days. Neither serious adverse event was unexpected 
based on the investigator brochure for seliciclib, and 
there were no deaths. No patients withdrew from the trial 
early due to uncontrolled rheumatoid arthritis symptoms, 
although three patients required intra-articular injections 
of corticosteroid as rescue therapy for rheumatoid 
arthritis, as permitted by the trial protocol.
65 non-serious adverse events were recorded during 
the trial, and 50 of these were defined as treatment 
related, being considered definitely, probably, or possibly 
caused by seliciclib (table 3). 20 of the treatment-related, 
non-serious adverse events contributed to dose-limiting 
toxicities (table 2; details of all non-serious adverse events 
for all participants, including their documented causal 
relation ship with seliciclib and contribution to 
Participants (n=15)




White British 15 (100%)
Disease duration, years 8 (3–30)
Swollen joint count 4 (0–11)
Tender joint count 10 (1–26)
DAS28–CRP score 4·9 (3·5–6·3)
Erythrocyte sedimentation rate, mm/h 9 (2–72)

















Methotrexate plus sulfasalazine plus 
hydroxychloroquine
1 (7%)
Data are median (range) or n (%). CRP=C-reactive protein. 
csDMARDs=conventional synthetic disease-modifying antirheumatic drugs. 
DAS28–CRP=Disease Activity Score for 28 joints–C-reactive protein. *Originator 
or biosimilar agents permitted. †Of the recipients of anti-TNF monotherapy at 
baseline, two received etanercept, two certolizumab, and one golimumab.
Table 1: Participant characteristics
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dose-limiting toxicities, are in the appendix pp 3–5). 
Treatment-related adverse events affecting the 
gastrointestinal system or liver function were common, 
with nausea being the most frequently reported 
treatment-related adverse event (14 [28%] of 50 adverse 
events). 12 (67%) of 18 terms used to describe treatment-
related adverse events indicated gastro intestinal or liver 
involvement, comprising 38 (76%) of 50 treatment-
related adverse events. The majority of adverse events at 
both seliciclib doses were mild, and all adverse events 
suspected to be related to treatment had resolved by the 
end of the trial, with the exception of two viral respiratory 
tract infections (which subsequently resolved) and one 
persistent elevation in aspartate aminotransferase 
concentration (3·5 times the upper limit of normal), 
which was nonetheless declining 2 weeks after seliciclib 
cessation. Adverse events, serious adverse events, and 
dose-limiting toxicities did not differ in frequency 
between the ten (67%) partici pants also taking 
background concomitant conventional synthetic 
DMARDs and the five (33%) on anti-TNF monotherapy. 
No request by a patient to stop treatment during the 
Figure 2: Dose-limiting toxicity occurrence by cohort and dose and Bayesian posterior probability of dose-limiting toxicity at each dose
(A) Dose limiting toxicity occurrence by cohort and dose level. Each box represents one patient. (B) Bayesian posterior probability of dose-limiting toxicity at each 
dose level (with 90% posterior probability intervals) following completion of cohort five. Dashed line at posterior probability of dose-limiting toxicity of 0·35; 
red point indicates value closest to target.








































































Patient 4 Two 52 Female 600 mg 4 Certolizumab ·· 3 0 Constipation, 
nausea, vomiting
Resolved
Patient 6 Two 64 Male 600 mg 1 Etanercept ·· 0 1† Fever, nausea, 
vomiting, acute renal 
injury
Resolved
Patient 9 Three 52 Female 400 mg 8 Adalimumab Sulfasalazine, 
hydroxychloroquine
















csDMARDs=conventional synthetic disease-modifying antirheumatic drugs. *Outcome of contributory adverse event or serious adverse event at close of follow-up. †Serious adverse events were classified as 
expected based on the investigator brochure.
Table 2: Summary of dose-limiting toxicities
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study followed an event considered unrelated to seliciclib 
by the investigating team.
Plasma seliciclib AUCs and Cmax measurements at 0, 2, 
4, and 6 h following seliciclib ingestion on day 1 and 
(where available) day 28 are shown in the appendix (pp 6, 8). 
As expected, AUC0–6 and Cmax values on day 1 of the 
first treatment cycle were higher among the three 
recipients of the 600 mg seliciclib dose in cohort two 
(AUC0–6 median 5753 ng/mL per h and Cmax 1560 ng/mL) 
than in the participants on the lower dose (AUC0–6 median 
2004 ng/mL per h and Cmax 655 ng/mL). Patients who 
subsequently had a dose-limiting toxicity had a higher 
median seliciclib AUC0–6 (4484 ng/mL per h) and Cmax 
(1249 ng/mL) than patients who did not have a dose-
limiting toxicity (median AUC0–6 2090 ng/mL per h and 
Cmax 637 ng/mL). The results were similar among patients 
who received the 400 mg seliciclib dose (ie, excluding 
cohort two), with the median AUC0–6 and Cmax values being 
approximately twice as high in patients who had 
dose-limiting toxicities compared with those who did not 
(results shown in full in the appendix p 6). Our sample 
size did not support formal inference testing, and the 
pharmacokinetic values for the two recipients of the 
400 mg dose who had serious adverse events fell within 
the relevant interquartile ranges. Nonetheless, these data 
raise the possibility of a relationship between toxicity and 
pharmacokinetic parameters that warrants further 
scrutiny in downstream studies. AUC0–6 and Cmax values 
were similar at day 1 and day 22 in patients for whom 
measurements at both timepoints were available. 
Pharmacodynamic parameters were not investigated 
because no dose reduction to 200 mg was triggered by the 
continual reassessment algorithm.
Among participants who were seropositive for 
rheumatoid factors, ACPA, or both on day 1 of seliciclib 
treatment, no change in measured autoantibody 
concentrations (measured as IU for rheumatoid factors 
and U/mL for ACPA) or status (positive vs negative 
according to local laboratory cutoffs) were observed 
during the trial (data not shown). Disease activity 
(DAS28–CRP) was recorded at 0, 2, and 4 weeks for 
nine (60%) of 15 participants who completed treatment. 
In a post-hoc analysis, a median change in DAS28–CRP 
score of –1·5 (range 0 to –4) was observed from week 0 to 
week 4 in these patients (figure 3; participant-level data 
for all 15 participants are shown in appendix p 9). 
Although fatigue was the descriptor for five adverse 
events (table 3), FACIT Fatigue scores (available for 
nine [60%] patients) showed no substantial change 
during the 4-week treatment course (score increased 
from median 27·0 [range 16 to 39] to 33·0 [17 to 51], 
indicating a diminution in fatigue; appendix p 10). 
HAQ-DI scores remained broadly stable during the trial 
(data not shown).
400 mg seliciclib dose (41 adverse events in 12 
participants)
600 mg seliciclib dose (9 adverse events in 3 
participants)
Total treatment-
related adverse events 
(% of total)
Mild Moderate Severe Mild Moderate Severe
Nausea 5 3 2 3 0 1 14 (28%)
Increased ALT 3 2 1 0 0 0 6 (12%)
Fatigue 2 2 1 0 0 0 5 (10%)
Diarrhoea 1 0 1 0 0 1 3 (6%)
Abdominal pain 0 0 1 2 0 0 3 (6%)
Increased AST 2 1 0 0 0 0 3 (6%)
Dizziness 2 0 0 0 0 1 3 (6%)
Increased ALP 2 0 0 0 0 0 2 (4%)
Heartburn 2 0 0 0 0 0 2 (4%)
Anorexia 1 0 0 0 0 0 1 (2%)
Increased bilirubin 1 0 0 0 0 0 1 (2%)
Flatulence 1 0 0 0 0 0 1 (2%)
Fever 1 0 0 0 0 0 1 (2%)
Vomiting 0 1 0 0 0 0 1 (2%)
Rhinitis 0 0 0 1 0 0 1 (2%)
Viral upper respiratory tract 
infection
1 0 0 0 0 0 1 (2%)
Viral lower respiratory tract 
infection
1 0 0 0 0 0 1 (2%)
Jaundice 0 0 1 0 0 0 1 (2%)
The terms fatigue and sleepiness are concatenated for purposes of reporting; as are heartburn and indigestion. ALP=alkaline phosphatase. ALT=alanine aminotransferase. 
AST=aspartate aminotransferase. 
Table 3: Treatment-related adverse events
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Discussion 
This study identified a maximum tolerated dose of 400 mg 
seliciclib in patients with active rheumatoid arthritis 
refractory to anti-TNF therapy, either as monotherapy or 
with background conventional synthetic DMARDs. To our 
knowledge, this is the first reported clinical trial expressly 
intended to target the hyperplastic, proliferative properties 
of synovial fibroblasts in rheumatoid arthritis, and the 
first rheumatology trial to use the Bayesian continual 
reassess ment method. Expansion of the synovial 
membrane into a pannus tissue, which actively erodes 
cartilage and bone while sustaining local inflammation, is 
a hallmark of rheumatoid arthritis; the process is 
dependent on the adoption by synovial fibroblasts of a 
proliferative and apoptosis-resistant pheno type. Our 
strategy of repurposing a CDK inhibitor to limit synovial 
fibroblast cell cycle progression affords an efficient 
development pipeline for drugs that, in reversing the 
quasi-malignant properties of these cells, might overcome 
ceiling effects of drugs targeting immune inflammation 
alone.
A few studies have targeted other properties of synovial 
fibroblasts, although examples in clinical development are 
rare. Efforts to disrupt the synovial membrane’s intrinsic 
cohesiveness during pannus development via 
cadherin-11 or integrin-α9—adhesion molecules that are 
expressed by synovial fibroblasts—have hitherto been 
unsuccessful.21–23 A study seeking to inhibit leukocyte 
chemotaxis by, and cross-talk with, synovial fibroblasts by 
targeting the synovial membrane-expressed chemokine 
CX3CL 1 (fractalkine) is ongoing.24 Our strategy might have 
parallel advantages, both restraining tissue-degrading 
proteinase expression and inhibiting pathological neutro-
phil and synovial macrophage function.25–27 The results of 
the phase 1b trial reported here are a crucial precursor to 
an ongoing phase 2a efficacy evaluation that is testing 
these hypotheses.
Application of the continual reassessment model 
approach in our dose-finding evaluation was efficient, 
with the maximum tolerated dose determined to a high 
confidence level after enrolment of 15 out of the permitted 
target of 21 participants (five cohorts of a possible seven). 
This illustrates an attractive feature of the adaptive 
Bayesian design, whereby progression of a drug with 
acceptable safety and tolerability parameters is not delayed 
by enrolment of analytically redundant participants in a 
more typical 3 + 3 phase 1 trial design, with the associated 
ethical and financial implications. Rather, such partici-
pants can be offered expedited enrolment into the follow-
on phase 2a trial. The application of adaptive trial designs 
in rheumatology is in its infancy28,29 but, given well 
documented challenges of recruitment to early phase 
clinical trials,30 our approach sets a valuable precedent and 
basis for the investigation of experimental investigational 
medicinal products for rheumatoid arthritis in the future.
Early phase oncology clinical trials with dosing schedules 
similar to that used in the current investigation indicated 
doses of 800 mg or more of seliciclib were safe and broadly 
acceptable to patients, albeit typically admini stered in 
divided daily doses.14 The somewhat lower, once-daily 
maximum tolerated dose of 400 mg observed in our study 
might reflect a reduced tolerability threshold among 
patients with rheumatoid arthritis with moderately active 
disease compared with patients with cancer diagnoses 
refractory to alternative therapy. This highlights the impor-
tance of recalibrating a drug’s posology for each new 
clinical indication. Such considerations are not new, with 
the anchor conventional synthetic DMARD metho trexate 
licensed for rheumatological indications at only a fraction 
of the dose used in haematological malignancies for which 
it was originally developed. The median plasma Cmax and 
AUC0–6 values for seliciclib among 12 recipients of the 
400 mg dose are compatible with pharmacological activity 
(Frame S, unpublished), and synovial tissue pharmaco-
dynamics form an important component of our phase 2a 
study.
Adverse events and dose-limiting toxicities in the 
current clinical trial were similar to the range of toxicities 
observed in oncology, with gastrointestinal reactions 
including liver enzyme abnormalities being the most 
common among these. This range of side-effects is 
familiar to rheumatologists and their patients, for whom 
nausea, anorexia, transaminitis, and fatigue are 
commonly associated with conventional synthetic 
DMARD use. A more generalised systemic upset, 
accompanied by fever and transient kidney injury as 
occurred in one recipient of the higher seliciclib dose in 
our study, is more rarely observed with licensed therapies, 
although it might be an idiosyncratic consequence of 
sulfasalazine use, for example. An increase in dose-
limiting toxicity rate was not observed when seliciclib 
was given in combination with background conventional 
Figure 3: DAS28–CRP scores before seliciclib and up to 4 weeks of treatment 
among patients who completed treatment
Each line shows the scores for one patient. DAS28–CRP=Disease Activity Score 
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synthetic DMARDs. On the contrary, four of five patients 
receiving anti-TNF mono therapy had a dose-limiting 
toxicity, whereas eight of ten patients who were receiving 
anti-TNF drugs and concomi tant conventional synthetic 
DMARDs did not. Caution should be exercised when 
considering this small sample size, but with anti-TNF 
monotherapy identifying a patient subgroup intolerant 
of multiple conventional synthetic DMARDs under 
current treatment guidelines,31 our observation seems to 
be consistent with clinical experience of a poorly 
understood phenomenon of treat ment intolerance in 
these patients. Similarly, the small sample size makes it 
difficult to confirm or exclude a relationship between 
pharmacokinetic parameters and toxicity, although our 
finding that patients with dose-limiting toxicities had 
median seliciclib AUC0–6 and Cmax values that were twice 
as high on day 1 of treatment cycle 1 compared with 
patients without dose-limiting toxicities suggests 
hypotheses to test in future studies. Such studies should 
also incorporate an assessment of pharma codynamic 
parameters in relation to both efficacy and toxicity.
This uncontrolled, phase 1a trial was not designed to 
assess efficacy, and the reduction of median DAS28–CRP 
observed among nine patients who completed treatment 
might represent regression to the mean, but no detrimental 
effect of the intervention on disease activity was suggested. 
Overall, although careful pharmacovigilance will be a 
feature of phase 2 seliciclib studies for rheumatoid 
arthritis, no impediment to their progression on safety 
grounds has been identified.
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